UY33468A - Agente terapeutico de liberacion sostenida para la hipertension y la disfunción renal - Google Patents

Agente terapeutico de liberacion sostenida para la hipertension y la disfunción renal

Info

Publication number
UY33468A
UY33468A UY0001033468A UY33468A UY33468A UY 33468 A UY33468 A UY 33468A UY 0001033468 A UY0001033468 A UY 0001033468A UY 33468 A UY33468 A UY 33468A UY 33468 A UY33468 A UY 33468A
Authority
UY
Uruguay
Prior art keywords
hypertension
renal dysfunction
therapeutic agent
discloses
blood pressure
Prior art date
Application number
UY0001033468A
Other languages
English (en)
Inventor
Shirakura Takashi
Tamura Mizuho
Takahashi Yoshimasa
Kuwahara Ippei
Original Assignee
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45371556&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY33468(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teijin Pharma Ltd filed Critical Teijin Pharma Ltd
Publication of UY33468A publication Critical patent/UY33468A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención da a conocer un agente terapéutico o preventivo para la hipertensión o la presión sanguínea alta normal, y para la disfunción renal, que es más eficaz que las drogas existentes. Más específicamente, la presente invención da a conocer una composición farmacéutica de liberación sostenida para el tratamiento o prevención de la hipertensión o la presión sanguínea alta normal, y para la disfunción renal, que comprende, como ingrediente activo, un compuesto de 2-feniltiazol representado por la siguiente fórmula (I) o una sal farmacéuticamente aceptable del mismo.
UY0001033468A 2010-06-25 2011-06-24 Agente terapeutico de liberacion sostenida para la hipertension y la disfunción renal UY33468A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2010145056 2010-06-25

Publications (1)

Publication Number Publication Date
UY33468A true UY33468A (es) 2012-01-31

Family

ID=45371556

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033468A UY33468A (es) 2010-06-25 2011-06-24 Agente terapeutico de liberacion sostenida para la hipertension y la disfunción renal

Country Status (25)

Country Link
US (1) US20130109726A1 (es)
EP (1) EP2586442A4 (es)
JP (1) JPWO2011162390A1 (es)
KR (1) KR20130088755A (es)
CN (1) CN102958521A (es)
AR (1) AR082022A1 (es)
AU (1) AU2011270133B2 (es)
BR (1) BR112012032543A2 (es)
CA (1) CA2803163A1 (es)
CL (1) CL2012003661A1 (es)
CO (1) CO6660504A2 (es)
EC (1) ECSP12012352A (es)
MA (1) MA34328B1 (es)
MX (1) MX2012015040A (es)
MY (1) MY160963A (es)
NZ (1) NZ605516A (es)
PE (1) PE20130241A1 (es)
RU (1) RU2013103366A (es)
SG (1) SG186798A1 (es)
TN (1) TN2012000568A1 (es)
TW (1) TW201215389A (es)
UA (1) UA107716C2 (es)
UY (1) UY33468A (es)
WO (1) WO2011162390A1 (es)
ZA (1) ZA201209388B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2582812B1 (en) 2010-06-16 2018-01-24 Takeda Pharmaceuticals U.S.A., Inc. Novel modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors
AU2011299153B2 (en) 2010-09-10 2014-10-30 Takeda Pharmaceuticals U.S.A., Inc. Methods for concomitant treatment of theophylline and febuxostat
JP5924699B2 (ja) * 2012-01-27 2016-05-25 帝人ファーマ株式会社 糖尿病の治療薬

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2073981C (en) 1990-11-30 2002-01-08 Shiro Kondo 2-arylthiazole derivatives and pharmaceutical composition thereof
US6998404B2 (en) * 2001-08-08 2006-02-14 Genomed, Llc Treatment or prevention of acute renal failure
CA2617248C (en) 2005-08-03 2015-09-29 Tap Pharmaceutical Products, Inc. Methods for treating hypertension
CN102008392B (zh) * 2005-08-18 2013-07-31 帝人制药株式会社 具有准确的用量分割功能的制剂
WO2008064015A1 (en) * 2006-11-13 2008-05-29 Takeda Pharmaceuticals North America Methods for preserving renal function using xanthine oxidoreductase inhibitors
CN101658505A (zh) * 2009-09-29 2010-03-03 北京华禧联合科技发展有限公司 非布索坦的缓释制剂及其制备方法
EP2582812B1 (en) * 2010-06-16 2018-01-24 Takeda Pharmaceuticals U.S.A., Inc. Novel modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors

Also Published As

Publication number Publication date
EP2586442A4 (en) 2014-01-01
CA2803163A1 (en) 2011-12-29
KR20130088755A (ko) 2013-08-08
ECSP12012352A (es) 2013-02-28
CL2012003661A1 (es) 2013-04-01
ZA201209388B (en) 2013-08-28
CN102958521A (zh) 2013-03-06
JPWO2011162390A1 (ja) 2013-08-22
TN2012000568A1 (en) 2014-04-01
BR112012032543A2 (pt) 2016-11-22
MA34328B1 (fr) 2013-06-01
CO6660504A2 (es) 2013-04-30
NZ605516A (en) 2015-02-27
US20130109726A1 (en) 2013-05-02
RU2013103366A (ru) 2014-07-27
WO2011162390A1 (ja) 2011-12-29
AR082022A1 (es) 2012-11-07
MX2012015040A (es) 2013-02-07
EP2586442A1 (en) 2013-05-01
AU2011270133A1 (en) 2013-01-10
PE20130241A1 (es) 2013-03-04
AU2011270133B2 (en) 2014-03-20
SG186798A1 (en) 2013-02-28
TW201215389A (en) 2012-04-16
UA107716C2 (ru) 2015-02-10
MY160963A (en) 2017-03-31

Similar Documents

Publication Publication Date Title
PH12018501807A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseas
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
SV2011004077A (es) Derivados aminobutiricos sustituidos como inhibidores de neprilisina
BR112013026257A2 (pt) derivados de glicosídeo e usos dos mesmos para o tratamento de diabetes
ECSP12012171A (es) Composiciones farmacéuticas del compuesto espiro-oxindol para administración tópica y sus usos como agentes terapéuticos
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
MY161001A (en) Tetrahydrocarboline Derivative
BR112012029170A2 (pt) fármaco antimalárico que contém ácido 5-aminolevulínico ou um derivado do mesmo como um princípio ativo
ECSP13012812A (es) Formulaciones inmunosupresoras
CR20140005A (es) Una nueva composición terapéutica que contiene apomorfina como principio activo
CO6400183A2 (es) Formas de dosificación oral de bendamustina
CR20150505A (es) Derivado de dihidropiridazin-3,5-diona
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico
UY35209A (es) Compuestos tricíclicos
UY30847A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
CO6280474A2 (es) Composicion farmaceutica para el tratamiento de la eyaculacion precoz
PE20151607A1 (es) Formulaciones de compuestos organicos
BR112012020377A8 (pt) utilização de um ou mais selecionado do grupo constituído por um composto da fórmula (i), uma mistura racêmica-diastereomérica e um isômero óptico do referido composto, e um sal farmaceuticamente aceitável e uma pródroga do mesmo, método, composição farmacêutica e kit para tratamento de caquexia e embalagem comercial
EA201270747A1 (ru) Композиции и способы для профилактики и лечения ран
ECSP12012352A (es) Agente terapéutico de liberación sostenida para la hipertensión y la disfunción renal
CO6290762A2 (es) Nuevos derivados quinazolin-2, 4-diona y una composicion farmaceutica para prevenir a tratar la enfermedad neurocerebral
PE20130308A1 (es) Metodos para tratar infecciones bacterianas recurrentes
BR112012024346A2 (pt) agente terapêutico ou agente profilático para a doença de alzheimer
BR112012020415A2 (pt) composição farmacêutica para a prevenção ou tratamento da osteoartrite

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20200615